A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer

Clinical Lung Cancer

Volumn 6, Issue 6, 2005, Pages 343-349

  Manegold, Christian ^a   Gatzemeier, Ulrich ^b   Buchholz, Erika ^a   Smith, Robert P ^c   Fandi, Abderrahim ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Clinical trial; Combination therapy; Efficacy; Epidermal growth factor receptor; Pharmacokinetics; Safety; Tyrosine kinase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; DOCETAXEL; GEFITINIB; METHYLPREDNISOLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLEEDING; BODY WEIGHT DISORDER; CANCER LOCALIZATION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; EYE TOXICITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GINGIVA BLEEDING; HEMOPTYSIS; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PILOT STUDY; PRURITUS; RHINITIS; SEPSIS; SKIN TOXICITY; STEADY STATE; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

EID: 26444536332     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.013     Document Type: Article

References (22)

1. Schottenfeld D. Etiology and epidemiology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, et al, eds. Lung Cancer: Principles and Practice of Oncology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000.
2. Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 2002; 7(suppl 4):9-15.
3. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61:3-13.
4. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
5. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations venus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
7. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.
8. Fossella FV, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354-2362.
9. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
10. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7(suppl 4):2-8.
11. Wells A. The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal 2000; 1:4-11.
12. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-250.
13. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
14. Gumerlock PH, Pryde BJ, Kimura T, et al. Enhanced cytotoxicity of docetaxel_OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2003; 22:662 (Abstract #2661).
15. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
16. Douillard J-Y, Natale R, Giaccone G, et al. ZD1839 ('Iressa') provides clinically significant antitumor activity and improves disease-related symptoms in pretreated patients with advanced non-small-cell long cancer (NSCLC): results of two phase II trials (IDEAL 1 and IDEAL 2). Eur J Cancer 2002; 38(suppl 7):S56-S57.
17. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
18. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145-157.
19. National Cancer Institute. Investigator's Handbook: A Manual for Participation in Clinical Trials of Investigational Agents. Cancer Therapy Evaluation Program, Division of Cancer Treatment. Bethesda, MD: National Cancer Institute, 2002.
20. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-253.
21. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290:2149-2158.
22. Rixe O, LeMarie E, Chomy F, et al. Phase II combination of gefitinib ('Iressa', ZD1839) and docetaxel for non-small-cell lung cancer: clinical results and biological monitoring. Proc Am Soc Clin Oncol 2003; 22:661 (Abstract #2659).